Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

Inclusion Criteria

• •Males who meet the criteria of obese, hypogonadotropic hypogonadism defined as:
• •* Patients with a Body Mass Index (BMI) ≥ 30 kg/m2
• •* Patients with a morning serum total testosterone level \< 300 ng/dL on at least two separate occasions during the Screening and/or Baseline periods.
• •* Patients with inappropriately low gonadotropins at screening given the low testosterone:
• •Luteinizing hormone (LH) ≤ ULN
• •Follicle stimulating hormone (FSH) ≤ ULN
• •Estradiol within or above the normal range (defined as ≥ LLN of the approved assay)
• •* Normal hypothalamic/pituitary function, including:
• •Prolactin: within the normal range
• •Thyroid stimulating hormone (TSH): within the normal range
• •Ferritin: within the normal range
• •Patients agree to use a barrier method of contraception (e.g., condom), for the duration of the study and for at least 3 months following their Study Completion visit to prevent BGS649 exposure to their partners.